BeOne Medicines (ONC) Revenue & Revenue Breakdown
BeOne Medicines Revenue Highlights
Latest Revenue (Y)
$3.81B
Latest Revenue (Q)
$1.32B
BeOne Medicines Revenue by Period
BeOne Medicines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $3.81B | 54.96% |
| 2023-12-31 | $2.46B | 73.65% |
| 2022-12-31 | $1.42B | 20.37% |
| 2021-12-31 | $1.18B | 280.83% |
| 2020-12-31 | $308.87M | -27.87% |
| 2019-12-31 | $428.21M | 116.03% |
| 2018-12-31 | $198.22M | -16.85% |
| 2017-12-31 | $238.39M | 22179.16% |
| 2016-12-31 | $1.07M | -87.86% |
| 2015-12-31 | $8.82M | -32.37% |
| 2014-12-31 | $13.04M | 16.93% |
| 2013-12-31 | $11.15M | - |
BeOne Medicines generated $3.81B in revenue during NA 2024, up 54.96% compared to the previous quarter, and up 889.80% compared to the same period a year ago.
BeOne Medicines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $1.32B | 17.72% |
| 2025-03-31 | $1.12B | -0.93% |
| 2024-12-31 | $1.13B | 12.60% |
| 2024-09-30 | $1.00B | 7.80% |
| 2024-06-30 | $929.17M | 23.62% |
| 2024-03-31 | $751.65M | 18.48% |
| 2023-12-31 | $634.41M | -18.80% |
| 2023-09-30 | $781.31M | 31.25% |
| 2023-06-30 | $595.26M | 32.93% |
| 2023-03-31 | $447.80M | 17.81% |
| 2022-12-31 | $380.10M | -1.94% |
| 2022-09-30 | $387.63M | 13.48% |
| 2022-06-30 | $341.57M | 11.40% |
| 2022-03-31 | $306.63M | 43.30% |
| 2021-12-31 | $213.98M | 3.65% |
| 2021-09-30 | $206.44M | 37.63% |
| 2021-06-30 | $149.99M | -75.24% |
| 2021-03-31 | $605.87M | 505.27% |
| 2020-12-31 | $100.10M | 9.90% |
| 2020-09-30 | $91.08M | 38.77% |
| 2020-06-30 | $65.64M | 26.08% |
| 2020-03-31 | $52.06M | -8.50% |
| 2019-12-31 | $56.89M | 13.46% |
| 2019-09-30 | $50.14M | -79.40% |
| 2019-06-30 | $243.35M | 212.65% |
| 2019-03-31 | $77.83M | 32.66% |
| 2018-12-31 | $58.67M | 8.24% |
| 2018-09-30 | $54.20M | 2.65% |
| 2018-06-30 | $52.80M | 62.25% |
| 2018-03-31 | $32.54M | 79.07% |
| 2017-12-31 | $18.17M | -91.75% |
| 2017-09-30 | $220.21M | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $393.00K | -41.95% |
| 2016-03-31 | $677.00K | -85.52% |
| 2015-12-31 | $4.68M | 238.91% |
| 2015-09-30 | $1.38M | - |
| 2015-06-30 | $1.38M | 0.07% |
| 2015-03-31 | $1.38M | -0.14% |
| 2014-12-31 | $1.38M | -78.74% |
| 2014-09-30 | $6.50M | 151.88% |
| 2014-06-30 | $2.58M | - |
| 2014-03-31 | $2.58M | - |
BeOne Medicines generated $1.32B in revenue during Q2 2025, up 17.72% compared to the previous quarter, and up 174.99% compared to the same period a year ago.
BeOne Medicines Revenue Breakdown
BeOne Medicines Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|
| Product | $1.77B | $1.66B | $1.40B |
| Collaboration | - | $13.22M | $8.75M |
Latest
BeOne Medicines's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Product (100.00%).
BeOne Medicines Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|
| All Other Countries Except China And United States Of America | $50.97M | $35.56M | $31.92M |
| CHINA | $439.88M | $432.92M | $399.59M |
| Europe | $166.58M | $152.38M | $118.55M |
| UNITED STATES | $754.86M | $694.43M | $567.21M |
Latest
BeOne Medicines's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (53.45%), CHINA (31.15%), Europe (11.79%), and All Other Countries Except China And United States Of America (3.61%).
BeOne Medicines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HUM | Humana | $117.76B | $32.65B |
| GEHC | GE HealthCare | $19.67B | $5.14B |
| PHG | Koninklijke Philips | $18.17B | $4.14B |
| IQV | IQVIA | $15.40B | $4.10B |
| ALC | Alcon | $10.09B | $2.46B |
| A | Agilent | $6.83B | $1.74B |
| RMD | ResMed | $5.15B | $1.34B |
| MTD | Mettler-Toledo | $3.87B | $1.03B |
| ONC | BeOne Medicines | $3.81B | $1.32B |
| NTRA | Natera | $1.70B | $592.18M |
| INSM | Insmed | $363.71M | $142.34M |